Measles: all 134 studies
Page 1 of 2. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 3
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 3
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT07338851
- Unravelling the Measles Paradox (MISIA)RecruitingNCT07267585
- Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation PatientsRecruitingNCT07195032Phase 4
- Prospective Clinical Registry for Evaluation of Exanthematous Infections and CoinfectionsNot yet recruitingNCT07112846
- Unravelling the Measles Paradox in ChildrenNot yet recruitingNCT06923631
- The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron DeficiencyRecruitingNCT06816524Not applicable
- Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 MonthsNot yet recruitingNCT06815835Phase 3
- Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden SettingsRecruitingNCT06667206Phase 2
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingNCT05952505Phase 4
- Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster VaccinationRecruitingNCT05894395Phase 3
- Co-administration Study of OCV, TCV and MRNot yet recruitingNCT05771779Phase 3
- Measles and BCG Vaccines for Mother and ChildRecruitingNCT04899765Phase 4
- Measles Vaccination at Health System ContactsEnrolling by invitationNCT04220671Phase 4
- Induction of Immunity Against Measles in Pediatric Liver Transplant RecipientsRecruitingNCT01770119Phase 4
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 2Results posted
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 2Results posted
- Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of AgeCompletedNCT03071575Phase 4Results posted
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedNCT02880865Phase 4Results posted
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 3Results posted
- Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second VaccinationCompletedNCT02158364Results posted
- Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First VaccinationCompletedNCT02151773Results posted
- Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderCompletedNCT02058563Phase 3Results posted
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgeCompletedNCT01702428Phase 3Results posted
- Coadministration of Measles-rubella and Rotavirus VaccinesCompletedNCT01700621Phase 4Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedNCT01621802Phase 3Results posted
- A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different DevicesCompletedNCT01557699Phase 1Results posted
- Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3Results posted
- Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenCompletedNCT01506193Phase 3Results posted
- Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of AgeCompletedNCT01346293Phase 3Results posted
- Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 3Results posted
- ProQuad Dose Selection Study (V221-011)(COMPLETED)CompletedNCT00986232Phase 2Results posted
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedNCT00985166Phase 3Results posted
- Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedNCT00985153Phase 3Results posted
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesCompletedNCT00984295Phase 3Results posted
- ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedNCT00975507Phase 3Results posted
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 3Results posted
- Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working SeedsCompletedNCT00892775Phase 2Results posted
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedNCT00861744Phase 2Results posted
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)TerminatedNCT00839917Phase 3Results posted
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 3Results posted
- Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy ToddlersCompletedNCT00626327Phase 3Results posted
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of AgeCompletedNCT00578175Phase 2Results posted
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)CompletedNCT00566527Phase 3Results posted
- Safety Study of ProQuad® rHA in Infants (V221-037)CompletedNCT00560755Phase 3Results posted
- Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3Results posted
- Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 3Results posted
- Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3Results posted
- ProQuad® Intramuscular vs SubcutaneousCompletedNCT00402831Phase 3Results posted
- A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3Results posted
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)CompletedNCT00326183Phase 4Results posted
- V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)CompletedNCT00109343Phase 3Results posted
- Predictors of Measles Vaccine Hesitancy in New York StateCompletedNCT07373093
- Barriers and Facilitators to MMR Vaccination Among Healthcare WorkersCompletedNCT06456788
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 3
- Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 MonthsCompletedNCT06387511Not applicable
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedNCT06331702Phase 4
- A Tool Kit to Improve Vaccine Confidence in the PhilippinesActive, not recruitingNCT06218368Not applicable
- Investigation of Immune Amnesia Following Measles Infection in Select African RegionsCompletedNCT06153979
- Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in SenegalTerminatedNCT05860920
- Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control TrialStatus unknownNCT05803538Not applicable
- Evaluation of Pediatric Measles Cases in 2019: Single-Center ExperienceCompletedNCT05614791
- Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases ConfirmedCompletedNCT05592756
- The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella VaccineStatus unknownNCT05279248Phase 4
- Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)Status unknownNCT05154097
- Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation TrialCompletedNCT04394689Phase 1/2
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps VaccineCompletedNCT04364399Phase 4
- Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)CompletedNCT04183114Phase 2/3
- Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, UgandaCompletedNCT04177485Not applicable
- Measles Vaccination Cash Incentives Experimental Evidence From NigeriaCompletedNCT04013516Not applicable
- Evaluation of an Infant Immunization Encouragement Program in NigeriaCompletedNCT03870061Not applicable
- Vaccine Campaign Effects on General Hospital Admissions and Mortality Among ChildrenCompletedNCT03460002Phase 4
- Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A VaccineStatus unknownNCT03330171Phase 4
- Randomized Controlled Trial of Measles Vaccination ScheduleStatus unknownNCT03170765Not applicable
- Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) VaccineCompletedNCT03160820Phase 4
- Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and RubellaCompletedNCT03148990Phase 2/3
- Phase I Trial of Measles Vectored Chikungungya VaccineCompletedNCT03028441Phase 1
- Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus AntibodiesCompletedNCT02934295Not applicable
- Mobile and Scalable Innovations for Measles Immunization: a Randomized Controlled TrialCompletedNCT02904642Not applicable
- MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.Status unknownNCT02712203
- mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-BissauStatus unknownNCT02662595Not applicable
- Immunogenicity of Co-administration of Measles and Japanese Encephalitis VaccinesCompletedNCT02643433Phase 4
- Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRCompletedNCT02325310Phase 4
- Early Waning of Maternal Measles and Meningitis C AntibodiesStatus unknownNCT02219061
- Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and RubellaCompletedNCT02196285Phase 1
- Immune Reconstitution to Measles Virus of HIV Infected Children in ZambiaCompletedNCT02058927
- Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.CompletedNCT01991899Phase 3
- Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western KenyaCompletedNCT01878435Not applicable
- Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)CompletedNCT01874457
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose PresentationsCompletedNCT01777529Phase 4
- Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy InfantsStatus unknownNCT01763268Phase 2/3
- Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the PhilippinesWithdrawnNCT01738841
- Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.CompletedNCT01668745Phase 4
- 300 Antibody Diagnostic Test KitStatus unknownNCT01646411
- Trial of Additional Measles Vaccine to Reduce Child MortalityCompletedNCT01644721Phase 4
- Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive FactorsStatus unknownNCT01602094
- Additional Measles Vaccine at 4 Months of AgeStatus unknownNCT01486355Phase 4